Discovery of small molecule antagonists of the USP5 zinc finger ubiquitin-binding domain. Read more about Discovery of small molecule antagonists of the USP5 zinc finger ubiquitin-binding domain.
Targeted protein degradation: expanding the toolbox. Read more about Targeted protein degradation: expanding the toolbox.
Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships. Read more about Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships.
Multiple direct interactions of TBP with the MYC oncoprotein. Read more about Multiple direct interactions of TBP with the MYC oncoprotein.
Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK). Read more about Towards the Development of an In vivo Chemical Probe for Cyclin G Associated Kinase (GAK).
A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors. Read more about A fast iterative synthetic approach towards the identification of novel highly selective p38 MAP kinase inhibitors.
Binding and structural analyses of potent inhibitors of the human Ca2+/calmodulin dependent protein kinase kinase 2 (CAMKK2) identified from a collection of commercially-available kinase inhibitors. Read more about Binding and structural analyses of potent inhibitors of the human Ca2+/calmodulin dependent protein kinase kinase 2 (CAMKK2) identified from a collection of commercially-available kinase inhibitors.
Emerging tools to investigate bromodomain functions. Read more about Emerging tools to investigate bromodomain functions.
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells. Read more about An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells.
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells. Read more about Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
